Menlo Therapeutics Inc. (Nasdaq: MNLO) reported disappointing results from a Phase 2 clinical trial of serlopitant to treat pruritus in adults and adolescents with a history of atopic dermatitis. Shares of the biopharmaceutical collapsed $27.05 to close at $8.17.
Disappointing study results for Menlo Therapeutics
April 09, 2018 at 19:26 PM EDT